Back to Ovarian Cancer
This trial is complete. It is no longer accepting participants. Results may be available on ClinicalTrials.gov.

NCT00138242

NCT00138242
Completed Phase 2

Who may be able to join

Who might be able to join this trial:

  • You have been diagnosed with ovarian, fallopian tube, or peritoneal cavity cancer that has been confirmed by a tissue sample (biopsy), and your cancer is at Stage IC or higher (up to Stage IV)
  • You have already had surgery to remove or reduce the cancer, or you are planning to have surgery after starting the study (some patients may receive chemotherapy before surgery first)
  • You are 18 years of age or older
  • You are reasonably well and able to carry out daily activities (confirm with trial site regarding fitness level assessment)
  • Your blood cell counts are at acceptable levels — including white blood cells, red blood cells, and platelets
  • Your liver function test results are within acceptable ranges
  • You are not pregnant or breastfeeding, and if you could become pregnant, you are willing to use reliable contraception during the trial and for at least 3 months after finishing treatment

Who may not be able to join:

  • Your tumor has been classified as "borderline" or "low malignant potential," regardless of stage
  • You have significant nerve damage or numbness/tingling in your hands or feet beyond a mild level
  • You have a history of another cancer that has a poor outlook and could come back during the trial period (the trial doctors will assess this)
  • You have previously had a severe allergic reaction to any medication containing an ingredient called polysorbate 80
  • You are currently receiving chemotherapy for a different cancer
  • Your liver function test results fall outside the acceptable ranges described for this trial (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.

Trial details

Status
Completed
Phase
Phase 2
Sponsor
Floyd & Delores Jones Cancer Institute at Virginia Mason Medical Center
Registry
clinicaltrials_gov
Start date
1 December 2004

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Reduction rate of myelosuppression

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 30 June 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

View original record on ClinicalTrials.gov